SCYX Shares Outstanding History



Below is a table of the SCYX shares outstanding history going back to 5/2/2014:

Date SCYX Shares Outstanding
5/2/2014845264
6/1/2014850206
8/1/2014850206
11/13/2014851210
3/1/2015851210
5/1/20151.39M
8/1/20151.39M
11/1/20151.39M
3/1/20161.39M
4/15/20161.39M
6/30/20162.34M
11/4/20162.40M
3/1/20172.55M
5/1/20172.58M
8/1/20172.67M
11/1/20172.86M
3/8/20184.68M
5/1/20184.68M
8/1/20184.70M
11/1/20184.80M
3/1/20195.01M
5/1/20195.37M
8/1/20195.57M
7/24/20195.30M
11/1/20195.84M
3/1/20209.74M
5/1/20209.86M
7/17/20209.86M
8/1/202010.60M
11/1/202010.94M
3/1/202120.62M
5/1/202120.63M
8/1/202123.22M
11/1/202123.95M
3/1/202228.94M
5/1/202232.58M
8/1/202232.65M
11/1/202232.66M
3/1/202333.32M
5/1/202336.52M
8/1/202337.18M
11/1/202337.21M

Also see: SCYX Market Cap History
SCYX YTD Return
SCYX Historical Shares Outstanding:
+48.90% CAGR
SCYX Historical Shares Outstanding: +48.90% CAGR

Mouse over chart for data details
5/2/2014 ...11/1/2023
SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis, respectively. Co. is also continuing on-going clinical studies of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients. We show 42 historical shares outstanding datapoints in our coverage of SCYX's shares outstanding history.

Understanding the changing numbers of SCYX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like SCYX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching SCYX by allowing them to research SCYX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree SCYX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
SCYNEXIS (SCYX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

SDC Shares Outstanding History
SDGR Shares Outstanding History
SEEL Shares Outstanding History
SEER Shares Outstanding History
SELB Shares Outstanding History
SEM Shares Outstanding History
SERA Shares Outstanding History
SESN Shares Outstanding History
SGEN Shares Outstanding History
SGFY Shares Outstanding History
More Healthcare companies »

 

SCYX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.